Free Trial

Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

Alnylam Pharmaceuticals logo
$165.04 +8.39 (+5.36%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$165.35 +0.31 (+0.19%)
As of 11/13/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alnylam Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
0
Hold
10
Buy
16

Based on 26 Wall Street analysts who have issued ratings for Alnylam Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 26 analysts, 10 have given a hold rating, 15 have given a buy rating, and 1 has given a strong buy rating for ALNY.

Consensus Price Target

$305.86
85.33% Upside
According to the 26 analysts' twelve-month price targets for Alnylam Pharmaceuticals, the average price target is $305.86. The highest price target for ALNY is $455.00, while the lowest price target for ALNY is $199.00. The average price target represents a forecasted upside of 85.33% from the current price of $165.04.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ALNY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ALNY Analyst Ratings Over Time

TypeCurrent Forecast
11/15/25 to 11/15/26
1 Month Ago
10/16/25 to 10/16/26
3 Months Ago
8/17/25 to 8/17/26
1 Year Ago
11/15/24 to 11/15/25
Strong Buy
1 Strong Buy rating(s)
4 Strong Buy rating(s)
3 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
15 Buy rating(s)
16 Buy rating(s)
16 Buy rating(s)
23 Buy rating(s)
Hold
10 Hold rating(s)
6 Hold rating(s)
5 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$305.86$361.43$393.86$482.17
Forecasted Upside85.33% Upside55.90% Upside75.36% Upside7.35% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

ALNY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ALNY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Alnylam Pharmaceuticals Stock vs. The Competition

TypeAlnylam PharmaceuticalsHealthcare CompaniesBroader Market
Consensus Rating Score
2.65
2.32
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside85.33% Upside115.11% Upside14.68% Upside
News Sentiment Rating
Neutral News

See Recent ALNY News
Positive News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
11/2/2026
Barclays PLC logo
Barclays
3 of 5 stars
Eliana Merle
Not Rated
Lower TargetOverweight$450.00 ➝ $380.00+136.30%
11/2/2026
Whitney Ijem
4 of 5 stars
Lower TargetBuy$429.00 ➝ $323.00+95.76%
11/2/2026
Truist Financial Corporation logo
Truist Financial
2 of 5 stars
Danielle Brill
Danielle Brill
4 of 5 stars
DowngradeBuy ➝ Hold$315.00 ➝ $225.00+36.36%
10/30/2026Lower TargetBuy$550.00 ➝ $329.00+94.12%
10/30/2026Reiterated RatingOutperform$290.00+66.67%
10/30/2026Reiterated RatingBuy$460.00 ➝ $287.00+64.94%
10/30/2026DowngradeStrong-Buy ➝ Outperform$420.00 ➝ $315.00+81.03%
10/30/2026Lower TargetBuy$425.00 ➝ $375.00+127.42%
10/30/2026Lower TargetOutperform$350.00 ➝ $320.00+94.06%
10/30/2026Lower TargetBuy$482.00 ➝ $354.00+111.28%
10/30/2026Lower TargetEqual Weight$300.00 ➝ $240.00+43.27%
10/30/2026Lower TargetBuy$536.00 ➝ $320.00+87.80%
10/30/2026Lower TargetEqual Weight$253.00 ➝ $220.00+29.10%
10/30/2026Lower TargetOutperform$345.00 ➝ $280.00+67.21%
10/30/2026DowngradeOutperform ➝ Market Perform$376.00 ➝ $199.00+11.69%
10/29/2026 Reiterated RatingHold (C)
10/29/2026Lower TargetBuy$357.00 ➝ $243.00+39.66%
10/29/2026DowngradeBuy ➝ Hold$225.00+19.29%
10/28/2026Reiterated RatingBuy
10/23/2026 DowngradeStrong-Buy ➝ Hold
10/14/2026Lower TargetBuy$340.00 ➝ $320.00+41.83%
9/30/2026 Reiterated RatingNeutral
9/30/2026Lower TargetOverweight$375.00 ➝ $369.00+47.01%
9/8/2026Boost TargetHold$230.00 ➝ $260.00-0.31%
2/17/2026 UpgradeHold ➝ Strong-Buy
12/15/2025Lower TargetMarket Perform$370.00 ➝ $351.00-10.26%
10/31/2025Reiterated RatingOverweight$449.00 ➝ $489.00+8.21%
9/11/2025Boost TargetOutperform$280.00 ➝ $515.05+9.93%
8/4/2025UpgradeUnderperform ➝ Peer Perform
8/1/2025Boost TargetSector Outperform$342.00 ➝ $450.00+12.00%
3/31/2025Initiated CoverageBuy$353.00+31.49%
3/21/2025 Reiterated RatingOutperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 11:06 PM ET.


Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, November 13, 2026. Please send any questions or comments about these Alnylam Pharmaceuticals pros and cons to contact@marketbeat.com.

Alnylam Pharmaceuticals
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.:

  • Alnylam Pharmaceuticals, Inc. recently reported a significant earnings beat for the quarter ended October 29, 2026, with actual earnings per share of $16.26 compared to the consensus estimate of $1.66, indicating strong profitability and operational efficiency that may drive future investor confidence.
  • The company announced five-year data from the HELIOS-B trial for its drug AMVUTTRA (vutrisiran) at the American Heart Association Scientific Sessions 2026, demonstrating sustained benefits in treating transthyretin amyloidosis with cardiomyopathy, which reinforces the long-term clinical value and market potential of its lead product.
  • Alnylam Pharmaceuticals, Inc. currently trades at $165.04, which is significantly below the consensus price target of $305.86 set by Wall Street analysts, suggesting substantial upside potential for investors who believe the market has overreacted to recent negative news.
  • Several major institutional investors, including Pictet Asset Management Holding SA and First Trust Advisors LP, significantly increased their stakes in the company during the third quarter of 2026, with Pictet boosting its position by 77.7%, indicating strong institutional conviction in the company's long-term prospects.
  • The stock has a low beta of 0.42, meaning it is less volatile than the overall market, which may appeal to risk-averse investors seeking stability in their biotechnology portfolio while still participating in the growth of RNA interference therapeutics.

Alnylam Pharmaceuticals
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons:

  • Alnylam Pharmaceuticals, Inc. is currently trading near its 52-week low of $149.18, having recently hit a new 52-week low of $154.30 on November 6, 2026, reflecting a significant decline from its 52-week high of $479.79 and indicating strong downward momentum in the stock price.
  • Multiple major financial institutions, including Goldman Sachs, Bank of America, and Oppenheimer, significantly lowered their price targets on the stock in late October 2026, with Goldman Sachs cutting its target from $536.00 to $320.00, signaling a more cautious outlook on the company's future earnings potential.
  • The company is facing a legal investigation by Pomerantz LLP on behalf of investors, as announced in November 2026, which could lead to costly litigation and distract management from operational goals, potentially impacting the company's financial performance and reputation.
  • Alnylam Pharmaceuticals, Inc. experienced a leadership change with the departure of its Chief Commercialization Officer, Tolga Tanguler, in November 2026, amid reports of a faltering trajectory for its key product AMVUTTRA, which may raise concerns about the company's ability to maintain market share and sales growth.
  • Short interest in the stock has been increasing in recent months, with shares shorted rising to 5,465,979 as of October 30, 2026, from 4,770,978 in August 2026, indicating that a growing number of traders are betting against the stock's future performance.

ALNY Forecast - Frequently Asked Questions

According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for Alnylam Pharmaceuticals is $305.86, with a high forecast of $455.00 and a low forecast of $199.00.

26 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 10 hold ratings, 15 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALNY shares.

According to analysts, Alnylam Pharmaceuticals's stock has a predicted upside of 85.33% based on their 12-month stock forecasts.

Over the previous 90 days, Alnylam Pharmaceuticals's stock had 5 downgrades and 3 upgrades by analysts.

Analysts like Alnylam Pharmaceuticals more than other "healthcare" companies. The consensus rating for Alnylam Pharmaceuticals is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how ALNY compares to other companies.


MarketBeat monitors more than a dozen sources for Alnylam Pharmaceuticals analyst ratings, with the most recent rating issued on 11/2/2026.
From Our Partners